How are you feeling today? Keep up to date on news and stories related to health care here!
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients
Surpassing $10M in revenue, Pulsetto processed nearly 40,000 orders in 2024. The company helped over 100,000 users manage stress and emotional well-being, and gained worldwide recognition as a frontrunner in longevity and health optimization. — Nearly half of the global
Zoetis plans to immediately implement updated label based on U.S. post-approval experience with Librela Company remains confident in the safety and effectiveness of Librela and reaffirms its commitment to supporting veterinarians and pet owners in helping dogs with OA live with less
Now accepting applications for 2025 grants to accelerate innovation in tissue transplantation EDISON, N.J. — (BUSINESS WIRE) — MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has awarded
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025
PARSIPPANY, N.J. — (BUSINESS WIRE) — YARAL Pharma Inc. (YARAL Pharma), the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today announced that it will continue working with the Pharmacy Podcast Network (PPN), a
First approval in the U.S. for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo’s DXd technology
OSAKA, Japan — (BUSINESS WIRE) — Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a $375 million project agreement through the Rapid